Product Description
Mechanisms of Action: Thrombin Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Fast Track - Mucopolysaccharidosis VI *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Mucopolysaccharidosis VI|Atrial Fibrillation|Thromboembolism|Pulmonary Embolism|Venous Thromboembolism|Embolism and Thrombosis|Venous Thrombosis|Mucopolysaccharidosis
Phase 1: Atrial Fibrillation
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2017-002158-35 | P2 |
Completed |
Mucopolysaccharidosis |
2019-10-22 |
|
| iMProveS | P2 |
Completed |
Mucopolysaccharidosis VI |
2019-09-24 |
23% |
| 2005-001256-20 | P2 |
Completed |
Atrial Fibrillation |
2006-12-28 |
|
| NCT00240643 | P2 |
Completed |
Atrial Fibrillation |
2006-12-01 |